A statement released earlier today by JP Morgan Cazenove about BTG PLC (LON:BTG) bumps the target price to 830.00GBX
- Updated: October 6, 2016
Yesterday BTG PLC (LON:BTG) traded 3.63% higher at 0.00GBX. The company’s 50-day moving average is 627.97GBX and its 200-day moving average is 640.80GBX. The last stock close price is down 10.62% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 355,500 shares of the stock were exchanged, down from an average trading volume of 588,749
JP Morgan Cazenove raised the target price of BTG PLC (LON:BTG) to 830.00GBX indicating a possible upside of 0%.
Previously on 10/06/2016, Stifel reported about BTG PLC (LON:BTG) held steady the target price at 640.00GBX. At the time, this indicated a possible downside of -0.06%.
See Chart Below
BTG PLC has a 52 week low of 504.00GBX and a 52 week high of 739.50GBX with a P/E ratio of 45.44 The company’s market cap is currently 0 GBX.
About BTG PLC (LON:BTG)
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.